Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.
Kenvue Inc. (NYSE: KVUE) is described as the world’s largest pure-play consumer health company by revenue, with a portfolio of science-backed brands such as Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Tylenol® and Zyrtec®. This news page aggregates company announcements, press releases and market-moving updates related to KVUE stock and Kenvue’s global consumer health operations.
Readers can find earnings news, including quarterly results where Kenvue reports net sales trends, organic sales performance, gross profit and operating income margins, and diluted and adjusted earnings per share. These releases often include management commentary on operating priorities, productivity initiatives, supply chain optimization efforts and updated outlooks for the fiscal year, along with explanations of non-GAAP measures such as Adjusted gross profit margin, Adjusted operating income margin, Adjusted net income, Adjusted EBITDA margin, Adjusted effective tax rate, Free cash flow and Organic sales.
The feed also covers strategic and corporate developments. In 2025, Kenvue announced a comprehensive review of strategic alternatives, leadership changes including a CEO transition, and a definitive agreement under which Kimberly-Clark Corporation will acquire all outstanding shares of Kenvue common stock in a cash and stock transaction, as detailed in joint press releases and a Form 8-K. Updates on this planned acquisition, board decisions and related shareholder communications are key topics for investors following KVUE news.
Additional items include dividend declarations by Kenvue’s Board of Directors, highlighting the company’s approach to returning capital to shareholders, and partnership and innovation news, such as the collaboration with Albert Invent to apply AI to Kenvue’s research and development processes. Together, these categories give investors, analysts and consumers a consolidated view of how Kenvue manages its brand portfolio, financial performance and strategic direction. Bookmark this page to quickly access the latest official Kenvue updates relevant to KVUE stock.
Neutrogena®, part of Kenvue Inc. (NYSE: KVUE), announced multi-year partnerships with dermatologists Dr. Dhaval Bhanusali and Dr. Muneeb Shah to enhance its dermatological beauty offerings. As Global Innovation Partners, they will focus on three key areas: innovation acceleration, consumer engagement, and dermatologist collaboration. The partnership aims to advance clinical science, improve product experience, and build consumer community engagement. This initiative reinforces Neutrogena's position as America's #1 facial skincare brand and strengthens its commitment to combining beauty with scientific innovation.
Starboard Value LP, an investment adviser, announced that its CEO Jeffrey Smith presented at the 2024 Active-Passive Investor Summit. The presentation highlighted value creation opportunities at three companies: Kenvue Inc. (NYSE: KVUE), Pfizer Inc. (NYSE: PFE), and Salesforce Inc. (NYSE: CRM).
The full presentation and individual company presentations are available on Starboard's website. Starboard Value LP focuses on investing in deeply undervalued companies and actively engages with management teams and boards to unlock shareholder value.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company by revenue, has announced it will release its third quarter 2024 financial results on November 7, 2024, before the market opens. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results.
Investors can access the conference call by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast will be available at investors.kenvue.com, with a replay accessible after the event. Kenvue's portfolio includes well-known brands such as Aveeno®, BAND-AID®, Johnson's®, Listerine®, Neutrogena®, and Tylenol®.
Kenvue Inc. (NYSE: KVUE), maker of iconic brands like Aveeno®, Listerine®, Neutrogena®, and Tylenol®, is advancing its climate action strategy through its Healthy Lives Mission. The company has released its first Task Force on Climate-related Financial Disclosures (TCFD) report, enhancing transparency and accountability.
Key progress includes:
- Reducing Scope 1 and 2 greenhouse gas emissions by 26% since 2020
- Increasing renewable electricity usage to 65% of total electricity consumption
- Validating near-term GHG reduction targets by the Science Based Targets initiative (SBTi)
- Increasing use of recyclable or refillable packaging to 71% of its portfolio
- Reducing virgin plastic in packaging by 21%
Kenvue is also engaging suppliers through its Supplier Climate Action Program and participating in various climate-focused coalitions to accelerate progress towards its environmental goals.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company, has announced its participation in the Barclays Global Consumer Staples Conference in Boston. CEO Thibaut Mongon, CFO Paul Ruh, and Chief Growth Officer Charmaine England will engage in a fireside chat on September 5, 2024, at 3:00 p.m. Eastern Time. The session will be available via live webcast on investors.kenvue.com, with a replay accessible afterward.
Kenvue boasts a portfolio of iconic brands including Aveeno®, BAND-AID®, Johnson's®, Listerine®, Neutrogena®, and Tylenol®. These brands are backed by science and recommended by healthcare professionals globally. The company emphasizes its commitment to everyday care and aims to empower consumers through its products.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company, is launching Neutrogena® Collagen Bank™, featuring patented micro-peptide technology. This launch targets the pre-aging skincare market, particularly appealing to Gen Z consumers concerned about early signs of aging.
The product line includes two moisturizers designed to defend and support natural collagen. Key features:
- Micro-peptides 2x smaller than leading anti-aging peptides
- Penetrates 10+ layers under skin surface
- Targets 5 markers critical for skin's firming support matrix
- Formulations for all skin tones and types, suitable for daily use
- Clinically proven to work on 5 early signs of collagen decline
The launch strategy includes an exclusive TikTok Shop debut before wider retail distribution, aiming to reach digitally native Gen Z consumers with an affordable skincare solution.
Kenvue Inc. (NYSE: KVUE) reported its Q2 2024 financial results, showing net sales of $4.0 billion, a 0.3% decrease year-over-year, with organic growth of 1.5%. The company's diluted EPS was $0.03, while adjusted diluted EPS reached $0.32. Kenvue's gross profit margin expanded by 360 basis points to 59.1%, and adjusted gross profit margin increased by 410 basis points to 61.6%. The company took a non-cash charge of $488 million related to the Dr.Ci:Labo® business impairment. Despite challenges, Kenvue reaffirmed its 2024 outlook, projecting net sales growth of 1.0%-3.0% and adjusted diluted EPS between $1.10-$1.20.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company, has announced changes to its Board of Directors. Kathleen M. Pawlus and Kirk L. Perry will join as new independent directors, effective August 15, 2024, and December 1, 2024, respectively. Pawlus, with over 40 years of experience in finance and operations, will serve on the Audit Committee. Perry, currently President and CEO of Circana, brings extensive consumer packaged goods and technology experience and will join the Compensation & Human Capital Committee.
Concurrently, Peter M. Fasolo and Joseph J. Wolk, current Johnson & Johnson executives, will resign from the Board in December 2024. This succession process aligns with Kenvue's commitment to independent Board oversight and follows Johnson & Johnson's divestment of its remaining stake in Kenvue in May 2024. By the 2025 Annual Meeting, Kenvue expects its Board to comprise 11 directors, with 10 being independent.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company by revenue, has announced a 2.5% increase in its quarterly dividend. The company's Board of Directors declared a $0.205 per share dividend on Kenvue common stock for the third quarter of 2024. This increase demonstrates Kenvue's commitment to returning cash to shareholders as part of its capital allocation strategy aimed at enabling sustainable growth and optimizing total shareholder return.
The dividend will be payable on August 28, 2024, to shareholders of record as of the close of business on August 14, 2024. Kenvue's portfolio includes iconic brands such as Aveeno®, BAND-AID®, Johnson's®, Listerine®, Neutrogena®, and Tylenol®, which are science-backed and recommended by healthcare professionals worldwide.
Kenvue (NYSE: KVUE), the leading global consumer health company, will release its second-quarter 2024 financial results on August 6, 2024, before the market opens. The results will cover the quarter ending June 30, 2024.
A conference call and webcast will follow at 8:30 a.m. Eastern Time to discuss the results. U.S. participants can dial 877-407-8835, while international participants can dial +1 201-689-8779 to join the call. The webcast will be available on Kenvue's investor relations website, with a replay accessible post-event.
Kenvue, known for brands like Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena, and Tylenol, emphasizes the importance of everyday care, with products supported by scientific research and healthcare professionals globally.
FAQ
What is the current stock price of Kenvue (KVUE)?
What is the market cap of Kenvue (KVUE)?
